Sicor Inc.

The Australian National University

Plus Chemicals Sa

Teva Pharmaceutical Industries Limited

Peter Lindsay MacDonald

Pierluigi Rossetto

Ettore Bigatti

Alexandr Jegorov

Adrienne Kovacsne-Mezei

Roman Gabriel

Ales Gavenda

Dorla Mirejovsky

Dario Tentorio

Zvi Harel

Augusto Canavesi

Rodney W Rickards

Jiri Faustmann

Gaia Banfi

Tony J Herlt

Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof.

Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof

Provided are polymorphs of fluticasone furoate and processes for preparation thereof.

Polymorphs of fluticasone furoate and process for preparation thereof

Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.

Process for the preparation of 7&#x3b1;-alkylated 19-norsteroids

The present invention provides processes for preparing Palonosetron salts, especially, the hydrochloride salt and intermediates used to prepare Palonosetron salts.

Processes for preparing palonosetron salts

The invention provides a high-yield process for the preparation of letrozole having a high purity, without the need for removal of the 4-[1-(1,3,4-triazolyl)methyl]benzonitrile impurity at the intermediate stage. The invention also provides a process for the synthesis of letrozole in which formation of the impurity 4-[1-(1,3,4-triazolyl)methyl]benzonitrile during the first stage is minimized. In the process, a 4-(halomethyl)benzonitrile is reacted with a salt of 1H-1,2,4-triazole, reducing the formation of the impurity. Preferably, the preparation is conducted as a one-pot process.

Process for the preparation of letrozole

This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.

Aqueous fludarabine phosphate composition

Dibenzo[b,d]pyrans are prepared by heating a dihydroxybenzoic acid derivative in the presence of a Lewis acid catalyst and an inert non-polar solvent in which the dihydroxybenzoic acid is soluble but in which the Lewis acid catalyst is insoluble or very slightly soluble. A typical embodiment involves the preparation of intermediates useful in the synthesis of dronabinol and related dibenzo[b,d]pyrans.

Growing community of inventors

Gentilino, Switzerland

Peter Lindsay MacDonald